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Abstract 
Incidence of melanoma is increasing every year. A few years ago, we could not speak about long term survivors 
with melanoma. Chemotherapy did not give a good effect in the past. Metastasis occurred very rapidly, and the 
progression of melanoma was very fast. But now, with new forms of therapy, especially immunotherapy and target 
therapy, for the first time, we have long-time survivors. For the prognosis of melanoma, the most important is the 
stage in which melanoma is detected. For all dermatologists, it is very important to be aware of the psychological 
impact of melanoma on patients. Dermatologists should recognise psychological disorders. Several different 
scales can be used for the detection of depression and anxiety – some of them are completed by researchers, 
some of them are completed by patients, and also, we have combined scales. The need for adequate social and 
family support as well as psychological help to achieve better coping with illness is necessary. Learning 
techniques to overcome fear and stress would help in better functioning of all affected, regardless of the stage of 
the disease. The most severe cases of anxiety and depression, in addition to psychotherapeutic interventions, 
should also be considered medication therapy. 
 
 
 
 
 
 
Introduction 
 
Incidence of melanoma is increasing every 
year. There are different sources with different data, 
very controversial, but it is evident increasing in 
incidence, especially in men over the age of 60. It is 
more frequent in young girls than in young men 
probably because of the use of the sunbeds. But, in 
Australia, New Zealand, the USA, North and Eastern 
Europe incidence is the highest. The fair-skinned, 
overexposed white population is in the greatest risk. 
A few years ago, we could not speak about 
long term survivors with melanoma. Chemotherapy 
did not give a good effect in the past. Metastasis 
occurred very rapidly, and the progression of 
melanoma was very fast. In young people, 
progression was even more aggressive. Living with 
melanoma was not considered and occurred very 
rarely. But now, with new forms of therapy, especially 
immunotherapy and target therapy, for the first time, 
we have long-time survivors. For the prognosis of 
melanoma, the most important is the stage in which 
melanoma is detected. If it is detected in the IA stage 
5-years survival is 97%, but if it is detected in the IV 
stage 5-years survival is only 15%. Living with 
melanoma is not easy, even if it is detected in the first 
stage. Follow up procedures every 3 or 6 months, 
laboratory testing, different examinations, surgery 
interventions, skin checking and other follow up 
procedures are very hard for all patients. Fear of the 
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progression of the disease is always present, even if it 
is diagnosed in the IA stage. Sometimes, but not so 
frequently, depression is also detected. We can 
mostly detect depressive symptoms, or minor 
depressive disorder and very rarely major depressive 
disorder. 
 
 
The most frequent psychological 
disorders and scales 
 
For all dermatologists, it is very important to 
be aware of the psychological impact of melanoma on 
patients. Dermatologists should recognise 
psychological disorders. Depressed mood, loss of 
interest/pleasure, significant weight loss or weight 
gain without trying to, insomnia or hypersomnia, 
psychomotor agitation/retardation, daily fatigue or loss 
of energy, feelings of worthlessness or excessive 
guilt, inability or difficulty with thinking, concentrating, 
and making decisions, suicidal thoughts, plans to 
commit suicide, or a suicide attempt. Sometimes, very 
rarely, we can detect symptoms of psychosis-
delusions or hallucinations. For the diagnosis of major 
depressive disorders, it is necessary coexistence of 5-
9 symptoms that last at least 2 weeks. For diagnosis 
of minor depressive disorder coexistence of 2 / 4 
symptoms that last at least 2 weeks are necessary. 
Dysthymic disorder is different, and it is characterised 
by the depressive mood that lasts longer than 2 years, 
with mostly 2-6 symptoms. 
Several different scales can be used for 
detection of depression – some of them are 
completed by researchers, some of them are 
completed by patients, and also, we have combined 
scales. Some of the scales completed by researchers 
are the Hamilton Depression Rating Scale, 
Montgomery-Åsberg Depression Rating Scale, Raskin 
Depression Rating Scale. But for dermatologists and 
screening programs, the most important are scales 
completed by patients. The Beck Depression 
Inventory is a scale that is in use very frequently. It 
consists of a 21-question, and it is self-report 
inventory that covers different symptoms that are 
present in depression such as fatigue, lack of interest 
in sex, weight loss, feelings of guilt, hopelessness, 
etc. The scale is completed by patients to identify the 
presence and severity of symptoms consistent with 
the DSM-IV diagnostic criteria. The next very 
frequently used self-reported questionnaire is 
The Patient Health Questionnaire (PHQ). The Patient 
Health Questionnaire-9 (PHQ-9) is a self-reported, 9-
question version of the Primary Care Evaluation of 
Mental Disorders and it is very useful for quick 
screening. The Patient Health Questionnaire-2 (PHQ-
2) is a shorter version of the PHQ-9 with only two 
questions to assess the presence of a depressed 
mood and a loss of interest or pleasure in routine 
activities. If it is detected, further testing is needed. 
Other scales that can be used are The Geriatric 
Depression Scale (GDS), Zung Self-Rating 
Depression Scale , The Clinically Useful Depression 
Outcome Scale (CUDOS), The Inventory of 
Depressive Symptomatology (IDS), The Mood and 
Feelings Questionnaire (MFQ), The Quick Inventory of 
Depressive Symptoms (QIDS), The Jacobson Joy 
Inventory (JJI)-Research in process-Banner University 
Medical Center, The Positive Health Questionnaire 
(PHQ) Research in process-Banner University 
Medical Center, etc. 
Anxiety is very frequent, and it can be 
detected in almost all patients with melanoma. It is a 
feeling of apprehension caused by anticipation of an 
ill-defined threat or danger that is not based. 
Components of anxiety are emotional, cognitive 
anticipation (memory), behavioural and somatic. 
There are different scales for measuring level of 
anxiety – Brief fear negative evaluation scale / BFNE, 
depression anxiety stress scales-DASS-21, 
Generalized anxiety disorder questionnaire IV – 
GADQ-IV, generalized anxiety disorder-GAD 7 (Table 
1), Hamilton Anxiety rating scale – HARS, Leibowitz 
social anxiety scale – LSAS, overall anxiety severity 
and impairment scale (OASIS), hospital anxiety and 
depression scale – HADS, patient health 
questionnaire 4 – PHQ-4, Penn state worry 
questionnaire – PSWQ, etc. 
Table 1: Depression and symptoms 
Major depressive 
disorder 
Minor depressive 
disorder 
Dysthymia 
Symptoms 
1. depressed mood 
2. loss of interest/pleasure 
3. significant weight loss or 
weight gain without trying to 
4. insomnia or hypersomnia 
5. psychomotor 
agitation/retardation 
6. daily fatigue or loss of 
energy 
7. feelings of worthlessness or 
excessive guilty 
8. inability or difficulty with 
thinking, concentrating and 
making decisions 
9. suicidal thoughts, plans to 
commit suicide, or a suicide 
attempt 
2 weeks duration  2 weeks duration 
2 years 
duration 
Depressed mood or 
loss of interest  
Depressed mood 
or loss of interest 
Depressed 
mood 
5 of 9 Symptoms  2-4 of 9 Symptoms 
2-6 
Symptoms 
 
For dermatologists, for fast screening, GAD-7 
and BAI are very useful. They are self-reported 
questionnaires, and very fast, and with a high-quality 
dermatologist can detect the level of anxiety (Table 2). 
Table 2: Generalized anxiety disorder- GAD 7 
Over the last 2 weeks, how often have you been 
bothered by the following problems? 
Not at 
all sure 
Several 
days 
Over 
half the 
days 
Nearly 
every 
day 
1. Feeling nervous, anxious, or on edge 0 1 2 3 
2. Not being able to stop or control worrying 0 1 2 3 
3. Worrying too much about different things 0 1 2 3 
4. Trouble relaxing 0 1 2 3 
5. Being so restless that it's hard to sit still 0 1 2 3 
6. Becoming easily annoyed or irritable 0 1 2 3 
7. Feeling afraid as if something awful might 
happen 
0 1 2 3 
Add the score for each column 
Total Score (add your column scores) = 
 
If dermatologist detects any level of anxiety or 
Vojvodic et al. Psychological Impact of Melanoma, How to Detect, Support and Help 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci. 2019 Sep 30; 7(18):3043-3045.                                                                                                                                                3045 
 
some of depressive symptoms, it is necessary to 
advise patient to visit psychologist, psychotherapist or 
psychiatrist. How patient will accept the disease 
depends very much on their mechanisms of defence. 
Also, support and help are necessary, the first from 
the family members, friends, colleges, but also from 
doctors/ dermatologists, and at the and professional 
help from psychiatrists, psychologists and 
psychotherapists. 
There are described mostly three general 
theoretical coping styles in the psycho-oncology 
literature: 1) Active-behavioral coping – this coping 
style refers to overt behavioural attempts to deal 
directly with cancer and its effects; 2) Active cognitive 
coping, this coping style includes one’s attitudes, 
beliefs, and thoughts about cancer; 3) Avoidance 
coping, this coping style refers to attempts to actively 
avoid the problem or indirectly reduce emotional 
tension through the use of distraction. All these 
mechanisms of coping are useful but not equally. 
In conclusion, the need for adequate social 
and family support as well as psychological help in 
order to achieve better coping with illness is 
necessary. Learning techniques to overcome fear and 
stress would help in better functioning of all affected, 
regardless of the stage of the disease. The most 
severe cases of anxiety and depression, in addition to 
psychotherapeutic interventions should also be 
considered medication therapy. The need for a 
multidisciplinary team that would be involved in 
monitoring the patient from the moment of the 
establishing the diagnosis of melanoma is of 
exceptional importance and include dermatologist, 
surgeon, radiotherapist, neurologist and psychiatrist, 
psychologist, psychotherapist. 
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